Featured Research

from universities, journals, and other organizations

Drug Offers New Hope For Victims Of Cardiac Arrest

Date:
September 20, 1999
Source:
University Of Washington
Summary:
A clinical trial performed by University of Washington researchers, reported in the Sept. 16 issue of the New England Journal of Medicine, shows that an intravenous anti-arrhythmia medication, amiodarone, can save the lives of many patients who do not respond to defibrillation.

The threat of imminent death awaits the 250,000 persons who suffer a cardiac arrest outside the hospital each year, especially those for whom defibrillation fails to shock the heart back to normal beating.

Related Articles


A clinical trial performed by University of Washington researchers, reported in the Sept. 16 issue of the New England Journal of Medicine, shows that an intravenous anti-arrhythmia medication, amiodarone, can save the lives of many patients who do not respond to defibrillation.

Dr. Peter Kudenchuk, associate professor of medicine and director of arrhythmia services at University of Washington Medical Center in Seattle, and colleagues performed the study, called ARREST (Amiodarone in the Out-of-Hospital Resuscitation of Refractory Sustained Ventricular Tacharrhythmias). The study was performed in conjunction with Medic One, Seattle/King County's highly regarded emergency response service based at Harborview Medical Center.

They found that resuscitation to a stable heart rhythm was improved by nearly 30 percent in people treated with intravenous amiodarone by emergency medical personnel at the scene of their collapse, compared to those who received other standard treatments for cardiac arrest.

This benefit was seen even when amiodarone was given late in the course of resuscitation, and was especially evident in women compared to men.

Kudenchuk noted that the clinical trial is the first of its kind to compare the effectiveness of an anti-arrhythmia medication with all standard treatments in victims of out-of-hospital cardiac arrest.

The drug was administered to 504 people in Seattle and surrounding King County, Wash., who suffered cardiac arrest due to a dangerous heart rhythm (ventricular fibrillation) and were treated at the scene by Medic One. Patients ranged in age from 20 to 94 years. The majority were men and the majority went into cardiac arrest at home.

"For every 10 persons treated with amiodarone for shock-resistant cardiac arrest, one additional person was resuscitated and admitted alive to the hospital," said Kudenchuk.

He noted that the main treatment endpoint for the ARREST trial was being successfully resuscitated and admitted to the hospital. The trial was not designed to evaluate the effect of amiodarone treatment on outcome after hospitalization. Although a small improvement in survival to hospital discharge with full recovery of brain function was observed in persons treated with amiodarone, the investigators did not feel that this difference was conclusive.

"Stopping the cardiac arrest and successfully getting patients to the hospital is a big step, but it's only the first hurdle," said Kudenchuk. "The next step is to determine whether drugs like amiodarone can improve long-term survival after cardiac arrest. "

Amiodarone is marketed as Cordarone IV by Wyeth-Ayerst Laboratories. The Medic One Foundation provided approximately two-thirds of the funding for the study and Wyeth-Ayerst, approximately one-third.


Story Source:

The above story is based on materials provided by University Of Washington. Note: Materials may be edited for content and length.


Cite This Page:

University Of Washington. "Drug Offers New Hope For Victims Of Cardiac Arrest." ScienceDaily. ScienceDaily, 20 September 1999. <www.sciencedaily.com/releases/1999/09/990920072033.htm>.
University Of Washington. (1999, September 20). Drug Offers New Hope For Victims Of Cardiac Arrest. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/1999/09/990920072033.htm
University Of Washington. "Drug Offers New Hope For Victims Of Cardiac Arrest." ScienceDaily. www.sciencedaily.com/releases/1999/09/990920072033.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Pot-Infused Edibles Raise Concerns in Colorado

Pot-Infused Edibles Raise Concerns in Colorado

AFP (Oct. 30, 2014) Colorado may have legalized marijuana for recreational use, but the debate around the decision still continues, with a recent - failed - attempt to ban cannabis-infused edibles. Duration: 01:53 Video provided by AFP
Powered by NewsLook.com
British Navy Ship Arrives in Sierra Leone With Ebola Aid

British Navy Ship Arrives in Sierra Leone With Ebola Aid

AFP (Oct. 30, 2014) The British ship RFA ARGUS arrived in Sierra Leone to deliver supplies and equipment to help the fight against Ebola. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins